Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

L2777

Sigma-Aldrich

Lisinopril

ACE Inhibitor

Synonym(s):

(S)-Nα-(1-Carboxy-3-phenylpropyl)-Lys-Pro

Sign Into View Organizational & Contract Pricing


About This Item

EC Number:
UNSPSC Code:
12352204
NACRES:
NA.26

Quality Level

General description

Lisinopril is a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. It is used in the treatment of heart failure and hypertension. Lisinopril is an antihypertensive and anticongestive agent, like other members of its family. It is water-soluble and possesses weak chelating properties.

Application

Lisinopril has been used as an angiotensin-converting enzyme (ACE) inhibitor:
  • in combination with spironolactone, to study their effects on cardiac and skeletal muscles in the Duchenne muscular dystrophy (DMD) mice model
  • standard in in vitro ACE inhibitory assay
  • as a negative control in ACE enzymatic assay

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Repr. 1A - STOT RE 2

Target Organs

Kidney

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Comparative Effects of Low and High Doses of the
Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on
Morbidity and Mortality in Chronic Heart Failure
Milton Packer
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale (2017)
E J Wallis et al.
Clinical pharmacology and therapeutics, 64(4), 439-449 (1998-11-03)
The antihypertensive response to angiotensin-converting enzyme (ACE) inhibitors may be attenuated by a compensatory decrease in atrial natriuretic factor production. If so, inhibition of atrial natriuretic factor breakdown by neutral endopeptidase (NEP) may enhance the antihypertensive effects of ACE inhibition.
Angiotensin converting enzyme inhibitors and moderate hypertension.
McAreave and Robertson Jl
Drugs (1990)
R L Hamlin et al.
Journal of veterinary internal medicine, 12(2), 93-95 (1998-04-30)
This study was designed to determine the degree of inhibition of the angiotensin-converting enzyme (ACE) in 5 normal dogs given single doses of conventionally used ACE inhibitors (ACEis). In addition the time required for that inhibition to return to 50%
M L Ricketts et al.
Clinical science (London, England : 1979), 96(6), 669-675 (1999-05-21)
In the kidney and colon 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) inactivates cortisol to cortisone, thereby protecting the non-selective mineralocorticoid receptor from cortisol. Deficiency of 11beta-HSD2 results in cortisol-mediated sodium retention and hypertension, suggesting that the physiological regulation of 11beta-HSD2 in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service